688073 毕得医药
已收盘 03-24 15:00:01
资讯
新帖
简况
股市必读:毕得医药(688073)今年截至3月23日累计跌幅已超20%
证券之星 · 03-24 02:39
股市必读:毕得医药(688073)今年截至3月23日累计跌幅已超20%
每周股票复盘:毕得医药(688073)现345.45万元大宗交易
证券之星 · 03-15
每周股票复盘:毕得医药(688073)现345.45万元大宗交易
3月13日毕得医药现345.45万元大宗交易
证券之星 · 03-13
3月13日毕得医药现345.45万元大宗交易
3月10日毕得医药涨5.05%,信澳健康中国混合A基金重仓该股
证券之星 · 03-10
3月10日毕得医药涨5.05%,信澳健康中国混合A基金重仓该股
毕得医药涨5.05%,开源证券一周前给出“买入”评级
证券之星 · 03-10
毕得医药涨5.05%,开源证券一周前给出“买入”评级
毕得医药(688073)披露使用自有资金支付募投项目并以募集资金等额置换的核查意见,3月9日股价下跌1.65%
证券之星 · 03-09
毕得医药(688073)披露使用自有资金支付募投项目并以募集资金等额置换的核查意见,3月9日股价下跌1.65%
每周股票复盘:毕得医药(688073)2025年净利增29.61%
证券之星 · 03-01
每周股票复盘:毕得医药(688073)2025年净利增29.61%
毕得医药发布2025年度业绩快报,盈利1.522亿元
证券之星 · 02-27
毕得医药发布2025年度业绩快报,盈利1.522亿元
毕得医药(688073)披露股东权益变动触及1%刻度的提示性公告,2月24日股价下跌0.72%
证券之星 · 02-24
毕得医药(688073)披露股东权益变动触及1%刻度的提示性公告,2月24日股价下跌0.72%
每周股票复盘:毕得医药(688073)现多笔折价大宗交易
中金财经 · 02-15
每周股票复盘:毕得医药(688073)现多笔折价大宗交易
2月12日毕得医药现1笔折价18.81%的大宗交易 合计成交1151.04万元
证券之星 · 02-12
2月12日毕得医药现1笔折价18.81%的大宗交易 合计成交1151.04万元
2月11日毕得医药现1笔折价20.89%的大宗交易 合计成交296.82万元
证券之星 · 02-11
2月11日毕得医药现1笔折价20.89%的大宗交易 合计成交296.82万元
2月9日毕得医药发生2笔大宗交易 成交金额475.2万元
证券之星 · 02-09
2月9日毕得医药发生2笔大宗交易 成交金额475.2万元
每周股票复盘:毕得医药(688073)现多笔折价大宗交易
证券之星 · 02-08
每周股票复盘:毕得医药(688073)现多笔折价大宗交易
股市必读:2月5日毕得医药现400.74万元大宗交易
证券之星 · 02-06
股市必读:2月5日毕得医药现400.74万元大宗交易
股市必读:2月2日毕得医药现1笔折价17.64%的大宗交易 合计成交206.88万元
证券之星 · 02-03
股市必读:2月2日毕得医药现1笔折价17.64%的大宗交易 合计成交206.88万元
每周股票复盘:毕得医药(688073)审议修订董高薪酬制度
证券之星 · 02-01
每周股票复盘:毕得医药(688073)审议修订董高薪酬制度
毕得医药拟修订董高薪酬制度,强化激励约束机制
中金财经 · 01-31
毕得医药拟修订董高薪酬制度,强化激励约束机制
毕得医药(688073)披露2026年第一次临时股东会会议资料,1月30日股价下跌9.04%
证券之星 · 01-30
毕得医药(688073)披露2026年第一次临时股东会会议资料,1月30日股价下跌9.04%
1月30日毕得医药跌9.04%,信澳健康中国混合A基金重仓该股
证券之星 · 01-30
1月30日毕得医药跌9.04%,信澳健康中国混合A基金重仓该股
加载更多
公司概况
公司名称:
上海毕得医药科技股份有限公司
所属行业:
研究和试验发展
上市日期:
2022-10-11
主营业务:
上海毕得医药科技股份有限公司的主营业务是为新药研发机构提供专业、高效的药物分子砌块及科学试剂产品及服务。公司的主要产品是分子砌块杂环化合物、分子砌块苯环化合物、分子砌块脂肪族类化合物、催化剂和配体、活性小分子化合物。
发行价格:
88.00
{"stockData":{"symbol":"688073","market":"SH","secType":"STK","nameCN":"毕得医药","latestPrice":52.55,"timestamp":1774335601000,"preClose":48.5,"halted":0,"volume":1443046,"delay":0,"changeRate":0.0835,"floatShares":43234200,"shares":90882900,"eps":1.6869,"marketStatus":"已收盘","change":4.05,"latestTime":"03-24 15:00:01","open":49.48,"high":52.78,"low":48.21,"amount":74005400,"amplitude":0.0942,"askPrice":52.57,"askSize":5,"bidPrice":52.55,"bidSize":2,"shortable":0,"etf":0,"ttmEps":1.6869,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774402200000},"marketStatusCode":5,"adr":0,"adjPreClose":48.5,"symbolType":"stock_kcb","openAndCloseTimeList":[[1774315800000,1774323000000],[1774328400000,1774335600000]],"highLimit":53.35,"lowLimit":43.65,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":90882948,"isCdr":false,"pbRate":2.39,"roa":"--","peRate":31.151817,"roe":"5.93%","epsLYR":1.32,"committee":-0.216216,"marketValue":4776000000,"turnoverRate":0.0334,"status":0,"afterMarket":{"amount":0,"volume":0,"close":52.55,"buyVolume":0,"sellVolume":0,"time":1774337637558,"indexStatus":"已收盘 03-24 15:30:00","preClose":48.5},"floatMarketCap":2272000000},"requestUrl":"/m/hq/s/688073","defaultTab":"news","newsList":[{"id":"2621086950","title":"股市必读:毕得医药(688073)今年截至3月23日累计跌幅已超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621086950","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621086950?lang=zh_cn&edition=full","pubTime":"2026-03-24 02:39","pubTimestamp":1774291150,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘,毕得医药报收于48.5元,下跌8.97%,换手率4.35%,成交量1.88万手,成交额9399.14万元。当日关注点来自交易信息汇总:毕得医药股价连续3日下跌,3月23日收盘报48.5元,跌8.97%。该股已连续3日下跌,当年累计跌幅20.05%。前10个交易日中,主力资金累计净流出1275.85万元,股价累计下跌14.14%;融资余额累计增加470.23万元,融券余量累计增加0股。最近90天内共有3家机构给予买入评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400002407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2619201861","title":"每周股票复盘:毕得医药(688073)现345.45万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2619201861","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619201861?lang=zh_cn&edition=full","pubTime":"2026-03-15 02:12","pubTimestamp":1773511933,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘,毕得医药报收于57.79元,较上周的57.61元上涨0.31%。本周关注点来自交易信息汇总:3月13日毕得医药现345.45万元大宗交易来自公司公告汇总:公司拟以自有资金先行支付募投项目款项,后续从募集资金专户等额置换交易信息汇总3月13日毕得医药发生一笔345.45万元的大宗交易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2619319198","title":"3月13日毕得医药现345.45万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2619319198","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619319198?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:23","pubTimestamp":1773393835,"startTime":"0","endTime":"0","summary":"证券之星消息,3月13日毕得医药发生大宗交易,交易数据如下:大宗交易成交价格53元,相对当日收盘价折价8.29%,成交6.52万股,成交金额345.45万元,买方营业部为浙商证券股份有限公司上海长乐路证券营业部,卖方营业部为浙商证券股份有限公司上海长乐路证券营业部。近三个月该股共发生16笔大宗交易,合计成交1.08万手,折价成交16笔。截至2026年3月13日收盘,毕得医药报收于57.79元,上涨2.27%,换手率3.1%,成交量1.34万手,成交额7679.4万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300029716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2618980584","title":"3月10日毕得医药涨5.05%,信澳健康中国混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618980584","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618980584?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:19","pubTimestamp":1773130794,"startTime":"0","endTime":"0","summary":"证券之星消息,3月10日毕得医药涨5.05%,收盘报59.52元,换手率3.29%,成交量1.42万手,成交额8385.97万元。重仓毕得医药的公募基金请见下表:该股最近90天内共有3家机构给出评级,买入评级3家。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共8家,其中持有数量最多的公募基金为信达澳亚基金的信澳健康中国混合A。信澳健康中国混合A目前规模为4.09亿元,最新净值2.184,较上一交易日下跌1.75%,近一年上涨16.52%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000024229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2618980560","title":"毕得医药涨5.05%,开源证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2618980560","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618980560?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:19","pubTimestamp":1773130784,"startTime":"0","endTime":"0","summary":"今日毕得医药涨5.05%,收盘报59.52元。2026年3月2日,开源证券研究员余汝意,石启正发布了对毕得医药的研报《公司信息更新报告:2025年业绩表现亮眼,经营态势稳步向好》,该研报对毕得医药给出“买入”评级。研报中预计公司2025-2027年归母净利润为1.52/2.27/2.84亿,对应EPS分别为1.68/2.50/3.13元/股,当前股价对应PE为34.8/23.3/18.6倍,维持“买入”评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为华创证券的万梦蝶。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000024226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","161027"],"gpt_icon":0},{"id":"2618627599","title":"毕得医药(688073)披露使用自有资金支付募投项目并以募集资金等额置换的核查意见,3月9日股价下跌1.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618627599","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618627599?lang=zh_cn&edition=full","pubTime":"2026-03-09 22:50","pubTimestamp":1773067824,"startTime":"0","endTime":"0","summary":"截至2026年3月9日收盘,毕得医药报收于56.66元,较前一交易日下跌1.65%,最新总市值为51.49亿元。该股当日开盘56.05元,最高57.05元,最低54.22元,成交额达8023.14万元,换手率为3.33%。近日,毕得医药发布《国泰海通证券股份有限公司关于上海毕得医药科技股份有限公司使用自有资金支付募投项目所需资金并以募集资金等额置换的核查意见》。因员工薪酬等支出需通过基本账户支付,公司拟使用自有资金先行支付募投项目部分款项,并定期从募集资金专户等额置换。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900035622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2616432648","title":"每周股票复盘:毕得医药(688073)2025年净利增29.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616432648","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616432648?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:15","pubTimestamp":1772302514,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘,毕得医药报收于58.29元,较上周的59.72元下跌2.39%。本周,毕得医药2月24日盘中最高价报60.47元。本周关注点业绩披露要点:毕得医药2025年归母净利润1.522亿元,同比增长29.61%。公司公告汇总上海毕得医药科技股份有限公司发布2025年度业绩快报,营业总收入132,381.07万元,同比增长20.13%;营业利润19,749.57万元,同比增长33.14%;归属于母公司所有者的净利润15,220.13万元,同比增长29.61%。总资产251,736.28万元,较年初增长4.11%;归属于母公司的所有者权益204,678.73万元,增长0.97%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2614835534","title":"毕得医药发布2025年度业绩快报,盈利1.522亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614835534","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614835534?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:17","pubTimestamp":1772183823,"startTime":"0","endTime":"0","summary":"证券之星消息,毕得医药近日即将发布2025年年报,根据2月27日发布的业绩快报,归属净利润盈利1.522亿元,同比增长29.61%。截至 2025 年末,公司总资产 251,736.28 万元,较年初上升 4.11%;归属于母公司的所有者权益 204,678.73 万元,较年初上升 0.97%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700028482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2613379741","title":"毕得医药(688073)披露股东权益变动触及1%刻度的提示性公告,2月24日股价下跌0.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613379741","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613379741?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:47","pubTimestamp":1771930033,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘,毕得医药报收于59.29元,较前一交易日下跌0.72%,最新总市值为53.88亿元。该股当日开盘60.19元,最高60.47元,最低59.05元,成交额达5055.12万元,换手率为1.96%。公司于近日披露《关于股东权益变动触及1%刻度的提示性公告》。本次权益变动后,信息披露义务人合计持股比例由10.00%减少至8.83%,触及1%刻度。本次减持为履行已披露的减持计划,不触及要约收购,未违反相关承诺,不影响公司治理结构及实际控制人稳定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400037681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2611670144","title":"每周股票复盘:毕得医药(688073)现多笔折价大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2611670144","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611670144?lang=zh_cn&edition=full","pubTime":"2026-02-15 08:04","pubTimestamp":1771113893,"startTime":"0","endTime":"0","summary":"h2,h3,h4{padding: 10px 0;font-size: 16px;line-height: 30px;color:#262626;font-weight: 600;}h2{border-bottom: 1px solid #d8dee4; padding-bottom: 0.3em}.article_content ul{padding-left:22px;}截至2026年2月13日收盘,毕得医药报收于59.72元,较上周的61.55元下跌2.97%。本周,毕得医药2月9日盘中最高价报62.69元。股本股东变化:2月13日公告,舟山欣曦、舟山兰旦合计减持106.47万股,占总股本1.1714%。公司公告汇总:2026年2月2日至12日,信息披露义务人持股比例由10.00%降至8.83%,触及1%刻度。2月12日毕得医药现1笔折价18.81%的大宗交易,合计成交1151.04万元。 2月9日毕得医药发生2笔大宗交易,成交金额475.2万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260215/32019273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2610894997","title":"2月12日毕得医药现1笔折价18.81%的大宗交易 合计成交1151.04万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610894997","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610894997?lang=zh_cn&edition=full","pubTime":"2026-02-12 17:42","pubTimestamp":1770889347,"startTime":"0","endTime":"0","summary":"证券之星消息,2月12日毕得医药发生大宗交易,交易数据如下:大宗交易成交价格49.2元,相对当日收盘价折价18.81%,成交23.4万股,成交金额1151.04万元,买方营业部为长江证券股份有限公司成都人民南路证券营业部,卖方营业部为浙商证券股份有限公司上海长乐路证券营业部。近三个月该股共发生17笔大宗交易,合计成交1.19万手,折价成交17笔。截至2026年2月12日收盘,毕得医药报收于60.6元,下跌1.16%,换手率2.7%,成交量1.17万手,成交额7132.03万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200029018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2610098020","title":"2月11日毕得医药现1笔折价20.89%的大宗交易 合计成交296.82万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610098020","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610098020?lang=zh_cn&edition=full","pubTime":"2026-02-11 17:30","pubTimestamp":1770802250,"startTime":"0","endTime":"0","summary":"证券之星消息,2月11日毕得医药发生大宗交易,交易数据如下:大宗交易成交价格48.5元,相对当日收盘价折价20.89%,成交6.12万股,成交金额296.82万元,买方营业部为兴业证券股份有限公司上海金陵东路证券营业部,卖方营业部为浙商证券股份有限公司上海长乐路证券营业部。近三个月该股共发生23笔大宗交易,合计成交1.5万手,折价成交23笔。截至2026年2月11日收盘,毕得医药报收于61.31元,上涨1.57%,换手率3.56%,成交量1.54万手,成交额9369.07万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100027879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2610635380","title":"2月9日毕得医药发生2笔大宗交易 成交金额475.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610635380","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610635380?lang=zh_cn&edition=full","pubTime":"2026-02-09 17:32","pubTimestamp":1770629560,"startTime":"0","endTime":"0","summary":"证券之星消息,2月9日毕得医药发生大宗交易,交易数据如下:近三个月该股共发生22笔大宗交易,合计成交1.44万手,折价成交22笔。该股近期无解禁股上市。截至2026年2月9日收盘,毕得医药(688073)报收于61.36元,下跌0.31%,换手率2.14%,成交量9256.0手,成交额5733.22万元。该股近半年内有股东持股变动,合计净减持102.24万股,股东增减持明细如下表:该股最近90天内共有2家机构给出评级,买入评级2家。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900022482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2609152686","title":"每周股票复盘:毕得医药(688073)现多笔折价大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2609152686","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609152686?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:28","pubTimestamp":1770488892,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘,毕得医药报收于61.55元,较上周的59.86元上涨2.82%。本周,毕得医药2月4日盘中最高价报63.8元。2月2日盘中最低价报58.28元。毕得医药当前最新总市值55.94亿元,在医疗服务板块市值排名32/51,在两市A股市值排名3216/5186。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2609588443","title":"股市必读:2月5日毕得医药现400.74万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2609588443","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609588443?lang=zh_cn&edition=full","pubTime":"2026-02-06 01:38","pubTimestamp":1770313089,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘,毕得医药报收于61.58元,下跌1.94%,换手率2.17%,成交量9364.0手,成交额5833.2万元。来自交易信息汇总:同日发生400.74万元大宗交易,显示存在一定规模的机构或大户间交易行为。交易信息汇总资金流向2月5日主力资金净流出857.9万元,占总成交额14.71%;游资资金净流入907.87万元,占总成交额15.56%;散户资金净流出49.97万元,占总成交额0.86%。大宗交易2月5日毕得医药现400.74万元大宗交易。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600001426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2608941458","title":"股市必读:2月2日毕得医药现1笔折价17.64%的大宗交易 合计成交206.88万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608941458","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608941458?lang=zh_cn&edition=full","pubTime":"2026-02-03 02:57","pubTimestamp":1770058629,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘,毕得医药报收于58.28元,下跌2.64%,换手率3.88%,成交量1.68万手,成交额9927.66万元。当日关注点来自交易信息汇总:2月2日毕得医药获主力资金净流入64.21万元,游资资金净流入480.73万元。大宗交易2月2日毕得医药现1笔折价17.64%的大宗交易,合计成交206.88万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300001747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2608077771","title":"每周股票复盘:毕得医药(688073)审议修订董高薪酬制度","url":"https://stock-news.laohu8.com/highlight/detail?id=2608077771","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608077771?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:30","pubTimestamp":1769887833,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘,毕得医药报收于59.86元,较上周的70.6元下跌15.21%。本周,毕得医药1月26日盘中最高价报72.2元。本周关注点公司公告汇总:审议《关于修订<董事、高级管理人员薪酬管理制度>的议案》公司公告汇总毕得医药:2026年第一次临时股东会会议资料上海毕得医药科技股份有限公司将于2026年2月9日召开2026年第一次临时股东会,审议《关于修订<董事、高级管理人员薪酬管理制度>的议案》。本次股东会由董事会召集,董事长戴岚主持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2607073042","title":"毕得医药拟修订董高薪酬制度,强化激励约束机制","url":"https://stock-news.laohu8.com/highlight/detail?id=2607073042","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607073042?lang=zh_cn&edition=full","pubTime":"2026-01-31 11:31","pubTimestamp":1769830266,"startTime":"0","endTime":"0","summary":"中访网数据 上海毕得医药科技股份有限公司于2026年1月24日发布公告,拟召开2026年第一次临时股东会,审议修订《董事、高级管理人员薪酬管理制度》的议案。该议案旨在规范公司董事及高级管理人员的薪酬管理,建立科学有效的激励与约束机制,以调动其积极性。议案已由公司第二届董事会第三十次会议审议通过。根据公告,本次临时股东会将于2026年2月9日上午9:30在上海市杨浦区公司会议室以现场结合网络投票的方式举行,网络投票通过上海证券交易所系统进行。会议将审议上述单一议案。此次制度修订是公司完善治理结构、优化高管激励体系的重要举措,预计将对公司长期人才稳定与战略执行产生积极影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260131/31989176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2607538042","title":"毕得医药(688073)披露2026年第一次临时股东会会议资料,1月30日股价下跌9.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607538042","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607538042?lang=zh_cn&edition=full","pubTime":"2026-01-30 23:16","pubTimestamp":1769786175,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘,毕得医药报收于59.86元,较前一交易日下跌9.04%,最新总市值为54.4亿元。该股当日开盘65.68元,最高66.57元,最低58.03元,成交额达2.27亿元,换手率为8.64%。近日,毕得医药发布2026年第一次临时股东会会议资料公告。公告显示,公司将于2026年2月9日召开2026年第一次临时股东会,审议《关于修订<董事、高级管理人员薪酬管理制度>的议案》。本次股东会由董事会召集,董事长戴岚主持。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000048196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2607846090","title":"1月30日毕得医药跌9.04%,信澳健康中国混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2607846090","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607846090?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:35","pubTimestamp":1769762132,"startTime":"0","endTime":"0","summary":"证券之星消息,1月30日毕得医药跌9.04%创60日新低,收盘报59.86元,换手率8.64%,成交量3.73万手,成交额2.27亿元。重仓毕得医药的公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级2家。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共8家,其中持有数量最多的公募基金为信达澳亚基金的信澳健康中国混合A。信澳健康中国混合A目前规模为4.09亿元,最新净值2.416,较上一交易日下跌1.02%,近一年上涨16.52%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000027847.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774395024627,"stockEarnings":[{"period":"1week","weight":-0.0743},{"period":"1month","weight":-0.1201},{"period":"3month","weight":-0.1953},{"period":"6month","weight":-0.3395},{"period":"1year","weight":-0.0338},{"period":"ytd","weight":-0.1392}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.0492},{"period":"3month","weight":-0.0151},{"period":"6month","weight":0.0073},{"period":"1year","weight":0.1517},{"period":"ytd","weight":-0.0221}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海毕得医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"3493人(较上一季度减少7.64%)","perCapita":"12377股","listingDate":"2022-10-11","address":"上海市杨浦区翔殷路128号11号楼A座101室","registeredCapital":"9088万元","survey":" 上海毕得医药科技股份有限公司的主营业务是为新药研发机构提供专业、高效的药物分子砌块及科学试剂产品及服务。公司的主要产品是分子砌块杂环化合物、分子砌块苯环化合物、分子砌块脂肪族类化合物、催化剂和配体、活性小分子化合物。","listedPrice":88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"毕得医药(688073)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供毕得医药(688073)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"毕得医药,688073,毕得医药股票,毕得医药股票老虎,毕得医药股票老虎国际,毕得医药行情,毕得医药股票行情,毕得医药股价,毕得医药股市,毕得医药股票价格,毕得医药股票交易,毕得医药股票购买,毕得医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"毕得医药(688073)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供毕得医药(688073)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}